Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Splash Beverage Group ( (SBEV) ).
On July 6, 2026, Splash Beverage Group announced an exclusive global licensing agreement with Argent BioPharma for CannEpil, a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy already available in markets including Ireland, the U.K., Germany and Australia. The deal gives Splash worldwide rights to develop and commercialize CannEpil for seizure-related neurological conditions, underpinning its strategic shift into cannabinoid therapeutics and exposure to a large unmet neurology market.
CannEpil has secured key regulatory and reimbursement milestones in Europe, including access under Ireland’s Medicinal Cannabis Access Program and prescription via the U.K.’s Named Patient framework, and has an IND number following pre-IND engagement with the U.S. FDA. The transaction structure includes forgiveness of about $5 million of Argent BioPharma debt, issuance of $5.5 million in Splash preferred equity, and a $1 million strategic investment from C/M Capital Partners, aligning stakeholders around long-term commercialization while positioning Splash to pursue U.S. clinical development and potential revenue growth.
Spark’s Take on SBEV Stock
According to Spark, TipRanks’ AI Analyst, SBEV is a Underperform.
The score is held down primarily by very weak financial performance (large ongoing losses, negative cash flow, and high leverage) and a clearly bearish technical trend (price below major moving averages with negative MACD). Valuation also screens poorly due to losses (negative P/E) and no dividend support.
To see Spark’s full report on SBEV stock,
click here.
More about Splash Beverage Group
Splash Beverage Group, Inc., headquartered in Fort Lauderdale, Fla., is a publicly traded company on the NYSE American that is repositioning itself as a cannabinoid-focused health, wellness and biopharmaceutical platform. The group aims to build this platform through disciplined capital allocation, strategic investments, acquisitions and related initiatives targeting regulated therapeutic markets.
Average Trading Volume: 18,862,966
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.36M
Find detailed analytics on SBEV stock on TipRanks’ Stock Analysis page.